Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326911 · ClinicalTrials.gov registry record · Phase 2
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00326911 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 61 participants.
The verdict
NCT00326911, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
Interventions
- DRUG gemcitabine
- BIOLOGICAL cetuximab
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326911
The ClinicalTrials.gov registry entry for NCT00326911 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gemcitabine is the first listed.
NCT00326911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326911 about?
NCT00326911 is a clinical study titled "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer". Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
What is the current status of trial NCT00326911?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00326911?
The interventions under investigation include: gemcitabine (DRUG), cetuximab (BIOLOGICAL), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00326911?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.